Netflix’s “Top 10 Today” shows what’s most watched — not what’s most worthwhile. A sensational reality show may outrank a thoughtful documentary that informs or inspires. Health policy decisions too frequently rely on a similar superficial metric: the CDC’s annual “Leading Causes of Death” list. But just as binge stats don’t tell you what’s worth watching, death rankings don’t tell you what’s worth prioritizing.
The list is widely cited by health officials, reporters, and manufacturers to signal burden or justify urgency. Yet it tells us little about where health interventions would do the most good. Understanding what causes the most deaths is useful — but only up to a point.
What the CDC’s “leading causes of death” list is used for
The CDC produces its “Leading Causes of Death” report on the basis of death certificate data. The 2023 rankings, in order, were:
- Heart disease
- Cancer
- Unintentional injuries
- Stroke
- Chronic lower respiratory disease
- Alzheimer’s disease
- Diabetes
- Chronic liver disease
- Kidney disease
- COVID-19
The CDC cites three purposes for this ranking: monitoring mortality trends, describing population health burden, and informing public health decision making. The rankings are simple and intuitive — but while they help us understand what’s common, they don’t help us decide what’s most important.
How manufacturers use leading causes of death to justify products and policy
Pharmaceutical and device manufacturers routinely use mortality rankings to frame disease burden and unmet need across audiences — regulators, payers, providers, and investors. The message is consistent: this condition causes many deaths, so addressing it is important, urgent, and valuable.
In regulatory communications, some manufacturers cite mortality rankings in FDA submissions to justify Breakthrough Therapy, Fast Track, or Emergency Use Authorization designations. High death tolls help to establish the seriousness of a condition.
In payer materials, some manufacturers use mortality data to argue for coverage and reimbursement. “Leading cause of death” language strengthens cases for favorable formulary placement and medical policies.
In provider education, mortality rankings attempt to highlight clinical relevance. Framing a disease as one of the top killers in the United States increases perceived importance and encourages adoption of new interventions.
In investor relations, mortality rankings help define market potential. A top-10 cause of death implies a large patient population and commercial upside.
Examples abound:
- Prevencio emphasized cardiovascular disease as “the leading cause of death in the United States and worldwide” when promoting its AI-based blood test
- Johnson & Johnson highlighted cardiovascular disease’s top ranking when acquiring Shockwave Medical
- Boston Scientific cited cardiovascular disease’s top ranking to justify innovation in vascular treatment
These statements follow a consistent pattern: identify a top-ranked disease to justify that your product addresses a critical need. But the logic is shallow. Prevalence doesn’t equal priority. A more nuanced measure of disease burden would better inform regulators, clinicians, and payers alike — but mortality rankings remain a powerful rhetorical shortcut across the health ecosystem. They continue to shape how manufacturers frame market potential, regulatory urgency, clinical relevance, and coverage appeal.
Limitations of the CDC’s top 10 leading causes of death list
It doesn’t reflect what’s actionable. Knowing that heart disease is #1 doesn’t identify which interventions — GLP-1s, statins, smoking cessation, food policy, surgical treatment — are most effective or scalable. It ignores feasibility, cost, or population reach.
It obscures preventability. The list doesn’t distinguish between highly preventable diseases (e.g., unintentional injuries, many infections) and biologically intractable ones. Policymakers need to know not just what kills, but what can be prevented effectively.
It treats all deaths equally. A death at 30 from overdose equals a death at 85 from chronic illness. But losing decades of potential life makes early mortality more impactful. The list doesn’t account for years of life lost, a measure that weights deaths by age to prioritize earlier mortality.
It ignores competing risks. Eliminating one cause of death doesn’t eliminate death — it often just shifts the timeline. Someone avoiding a fatal stroke may later die from cancer. Epidemiologists call this competing risks: preventing one cause can increase probability of another, especially in older adults with multiple conditions.
It fails to identify the cost-effectiveness of an intervention. Health economists frame this in terms of marginal impact on life expectancy. The key question isn’t “Can a death be prevented?” but “How many additional years of life will prevention provide?” Lower-ranked conditions like opioid overdose or suicide may yield more life-years saved per intervention than top-ranked diseases affecting older populations.
It is less relevant to payers. Insurers and plan sponsors tend to focus on conditions that drive costs — such as avoidable hospitalizations, complex chronic care, or repeated use of emergency services rather than conditions defined by mortality alone
It flattens disparities. National rankings mask devastating burdens on particular groups by race, ethnicity, income, or geography. A disease may not break into the national Top 10 but still represent a local or demographic crisis.
Better metrics than leading causes of death for policy decisions
Several frameworks offer a more nuanced view of health burden than raw death counts. They help identify what’s truly impactful, preventable, and worth prioritizing.
Years of Life Lost (YLL) weights deaths by age, highlighting causes that rob people of the most potential life. Suicide doesn’t appear in the top 10 for all ages but contributes disproportionately to YLL because it often occurs under age 40. Alzheimer’s disease ranks #6 but typically affects people in their 80s and 90s, resulting in fewer years lost per death.
Disability-Adjusted Life Years (DALYs) combine years lost to death with years lived in poor health, capturing both fatal and nonfatal burdens. Major depressive disorder ranks among the top DALY contributors globally due to chronic mental health impacts, yet it doesn’t appear in death rankings. Low back pain — the leading cause of disability worldwide—causes no deaths but enormous health burden. These conditions are largely invisible in mortality lists but account for a substantial share of the disease burden.
Preventable deaths estimate lives savable with better health care, lifestyle changes, or policy reforms. This highlights where current interventions — tobacco taxes, safer roads, overdose prevention — could have a measurable difference in population health. Many unintentional injuries, which together make up the third-leading cause of death, are highly preventable — while conditions like Alzheimer’s currently offer few prevention avenues.
Age-adjusted death rates control for differences in population age structure, enabling fair comparisons across time and place. Heart disease remains the leading absolute cause, but its age-adjusted rate has declined substantially. Liver disease shows rising age-adjusted rates among younger adults despite not ranking in the top 5.
Cost-effectiveness analysis evaluates which interventions provide the greatest health benefit per dollar. Tobacco-control programs are broadly effective and relatively inexpensive. High-cost late-stage therapies may yield small gains at great expense. Groups like the Institute for Clinical and Economic Review use both quality-adjusted life years (QALYs) and equal value of life years gained (evLYG) to assess which interventions offer the most health benefit per dollar spent.
Why health policy needs more than a list of leading causes of death
The CDC’s list serves valid purposes — tracking trends and offering intuitive snapshots of American mortality. But like Netflix’s Top 10, it shows what’s most visible, not what’s most important.
If we want health policy decisions about funding, regulation, or innovation to reflect true need and opportunity, we must go beyond ranked lists. That means triangulating mortality data with complementary measures — such as years of life lost, disability burden, preventability, and cost-effectiveness — to guide more effective decisions. Each offers a different lens. Together, they provide a fuller picture of what matters: not just what kills, but what can be saved, improved, and made more just.
What’s most watched isn’t always what’s worth watching. And what kills the most isn’t always what’s worth tackling first.
No Comments